|
Tecentriq (atezolizumab) and Avastin (bevacizumab): Atezolizumab in combination with bevacizumab is NOT approved as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation and the benefit-risk profile does not support the use of atezolizumab plus bevacizumab in this setting
|
|
Actemra (tocilizumab)
|
|
Guide for doctors with information on the use of the drug Rufixalo (rivaroxaban)
|
|
Integrilin (eptifibatide)
|
|
Lefluonia
|
|
Tecentriq (atezolizumab)
|
|
Zometa (zoledronic acid) - risk of osteonecrosis of the jaw
|
|
L-Thyroxin Berlin-Chemie (levothyroxine) new formulation tablets: monitoring of patients switching between tablets
|
|
Therapy guide with Vsiqq (brolucizumab)
|
|
Actemra (tocilizumab)
|
